Yarrow Bioscience, Inc. (YARW) income statement
YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30105% above fair value
$14.23−0.12 (-0.84%)
Close on Nov 19, 2026Market cap $37.99MP/E –Yield –
Yarrow Bioscience, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -5219.1%
- Net margin
- -4646.1%
- Return on equity, FY2025
- -66.3%
Financial strength
- Current ratio
- 15.26
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1486.7%
Valuation
- P/E ratio
- –
- Price to sales
- 66.65
- Price to book
- 1.72
- Dividend yield
- –
See a number that looks wrong?